ABSTRACT

More than half of cancer patients receive ionizing radiation as part of their treatment and it is the main modality at advanced stages of disease. Treatment outcomes in radiotherapy are determined by complex interactions between cancer genetics, treatment regimens, and patient-related variables. A typical radiotherapy treatment scenario can generate a large pool of data, “Big data,” that is comprised of patient demographics, dosimetry, imaging features, and biological markers. Radiotherapy data constitutes a unique interface between physical and biological data interactions. In this chapter, the authors review recent advances and discuss current challenges to interrogate big data in radiotherapy using top-bottom and bottom-top approaches. They describe the specific nature of big data in radiotherapy and discuss issues related to bioinformatics tools for data aggregation, sharing, and confidentiality. The authors also highlight the potential opportunities in this field for big data research from bioinformaticians as well as clinical decision-makers’ perspectives.

INTRODUCTION

Cancer is a leading cause of mortality in the United States and worldwide. It remains the second most common cause of death in the United States, accounting for nearly 1 of every 4 deaths. It is projected that a total of 1,665,540 new cancer cases and 585,720 cancer deaths are to occur in the United States in 2014 (Siegel, Ma, Zou, & Jemal, 2014). Radiation therapy (radiotherapy) is one of three major treatment modalities of cancer beside surgery and chemotherapy and it remains the main option at locally advanced stages of the disease. More than half of all cancer patients receive radiotherapy as a part of their treatment. Despite radiotherapy proven benefits, it comes with a Damocles’ sword of benefits and risks to the exposed patient. A key goal of modern radiation oncology research is to predict, at the time of radiation treatment planning, the probability

DOI: 10.4018/978-1-4666-6611-5.ch008
The Role of Big Data in Radiation Oncology

of tumour response benefits and normal tissue risks for the type of treatment being considered. Although recent years have witnessed tremendous technological advances in radiotherapy treatment planning, image-guidance and delivery, efforts to individualize radiotherapy treatment doses based on in vitro assays of various biological endpoints has not been clinically successful (IAEA, 2002; C. M. West, 1995). Conversely, several groups have shown that dose-volume factors play an important role in determining treatment outcomes (Bentzen et al., 2010; Blanco et al., 2005; J. Bradley, Deasy, Bentzen, & El-Naqa, 2004; J. O. Deasy & El Naqa, 2008; I. El Naqa et al., 2006; Hope et al., 2005; Jackson et al., 2010; Marks, 2002a; Tucker et al., 2004), but these methods may suffer from limited predictive power when applied prospectively. The lack of progress or major breakthroughs in radiotherapy outcomes over the past two decades demands fundamentally new insights into the methodologies used to better exploit the power of this unique non-invasive high-energy source, as well as it requires a new vision to guide the analysis of radiotherapy response and the design of new therapeutic strategies.

Outcomes in radiotherapy are usually characterized by tumour control probability (TCP) and the surrounding normal tissues complications (NTCP) (Steel, 2002; Webb, 2001). Traditionally, these outcomes are modeled using information about the dose distribution and the fractionation scheme (Moissenko, Deasy, & Van Dyk, 2005). However, it is recognized that radiation response may also be affected by multiple clinical prognostic factors (Marks, 2002b) and more recently, inherited genetic variations have been suggested as playing an important role in radiation sensitivity (J. Alsner, C. N. Andreassen, & J. Overgaard, 2008; C. M. L. West, Elliott, & Burnet, 2007). Moreover, evolution in imaging and biotechnology have provided new extraordinary opportunities for visualizing tumours in vivo and for applying new molecular techniques for biomarkers discovery of radiotherapy response, respectively (Bentzen, 2008; Jain, 2007; Nagaraj, 2009; C. M. L. West et al., 2007). However, biological assays, which can be performed on either tumour or normal tissues, may not be the only determinant of tumour control or risk of radiotherapy adverse reactions. Therefore, recent approaches have utilized data driven models using advanced informatics tools in which dose-volume metrics are mixed with other patient or disease-based prognostic factors in order to improve outcomes prediction (Issam El Naqa, 2012). Accurate prediction of treatment outcomes would provide clinicians with better tools for informed decision-making about expected benefits versus anticipated risks.

In this chapter, we will provide an overview of recent advances in radiotherapy informatics and discuss current challenges to interrogate big data as it appears in radiotherapy using top-bottom and bottom top-approaches. We will describe the specific nature of big data in radiotherapy, and the role of the emerging field of systems radiobiology for outcomes modeling. We will provide examples based on our and others experiences. Finally, we will discuss issues related to bioinformatics tools for data aggregation, sharing, and confidentiality.

BACKGROUND

Radiotherapy of Cancer

Radiotherapy is targeted localized treatment using ablative high-energy radiation beams to kill cancer cells. More than half of all cancer patients, particularly patients with solid tumours such as in the brain, lung, breast, head and neck, and the pelvic area receive radiotherapy as part of their curative or palliative treatment. A typical radiotherapy planning process would involve the acquisition of patient image data (typically fully 3-D computed tomography (CT) scans and other diagnostic imaging modalities such as positron emission tomography (PET) or magnetic resonance imaging (MRI)). Then, the physician